Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for eczema sufferers with painful itchy nodules?

NCT ID NCT05451316

Completed Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug upadacitinib in people with moderate to severe atopic dermatitis (eczema) who also have prurigo nodularis, a condition causing intense itching and hard bumps. The goal was to see if the drug reduces itching and improves skin. The study was observational and took place in Japan, with participants taking upadacitinib daily for 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
upadacitinib (oral tablet)
What this could lead to
If successful, this could confirm that upadacitinib effectively reduces severe itching and nodules in people with atopic dermatitis and prurigo nodularis.
What could go wrong
This is a small, observational study with only one participant enrolled, so results may not apply to a broader population. Upadacitinib also carries risks like infections and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

  • Tohoku Medical and Pharmaceuti /ID# 252486

    Sendai, Miyagi, 983-0005, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.